OUTPATIENT PHARMACOTHERAPY

for Neonatal Abstinence Syndrome



Neonatal abstinence syndrome (NAS) is a withdrawal syndrome in infants born to mothers who used opioids during pregnancy

Among **TN infants** covered by Medicaid born *from* **2009-20II**:





The median

length of treatment Was

19 days for inpatients &
60 days for outpatients

Outpatient therapy was longer

36%

42%

% **inpatient** & **outpatient** infants with at least one emergency department visit within six months



ED utilization H | G H E R for outpatients



of outpatient infants with NAS were treated with phenobarbital

The sedative phenobarbital has been associated with pook neurologic outcomes.



Providers should be cautious when discharging NAS patients on medication



Maalouf, F.I., Cooper, W.O., Slaughter, J.C., Dudley, J., & Patrick, S.W. (2018). Outpatient Pharmacotherapy for Neonatal Abstinence Syndrome. The Journal of Pediatrics, 7(I). Funding: NIH National Institute on Drug Abuse Grant K23DA038720.

